Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E; SPARTACUSS Group. Patrikidou A, et al. Among authors: sweeney c. Clin Genitourin Cancer. 2024 Oct 5;22(6):102230. doi: 10.1016/j.clgc.2024.102230. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39461026 Free article.
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E; Spartacuss Group. Fotia G, et al. Among authors: sweeney c. Clin Genitourin Cancer. 2024 Oct;22(5):102185. doi: 10.1016/j.clgc.2024.102185. Epub 2024 Aug 9. Clin Genitourin Cancer. 2024. PMID: 39217072 Free article.
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.
Ravi P, Wang V, Fichorova RN, McGregor B, Wei XX, Basaria S, Sweeney CJ. Ravi P, et al. Endocr Relat Cancer. 2023 Oct 4;30(11):e230241. doi: 10.1530/ERC-23-0241. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37671811 Free PMC article. Clinical Trial.
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E, D'Haese D, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn DJ, Sternberg CN, Heidenreich A, Collette L, Gillessen S, Beyer J. Bührer E, et al. Among authors: sweeney cj. Eur J Cancer. 2024 May;202:114042. doi: 10.1016/j.ejca.2024.114042. Epub 2024 Mar 30. Eur J Cancer. 2024. PMID: 38564927
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
Lauritsen J, Sauvé N, Tryakin A, Jiang DM, Huddart R, Heng DYC, Terbuch A, Winquist E, Chovanec M, Hentrich M, Fankhauser CD, Shamash J, Del Muro XG, Vaughn D, Heidenreich A, Sternberg CN, Sweeney C, Necchi A, Bokemeyer C, Bandak M, Jandari A, Collette L, Gillessen S, Beyer J, Daugaard G. Lauritsen J, et al. Among authors: sweeney c. Br J Cancer. 2023 Nov;129(11):1759-1765. doi: 10.1038/s41416-023-02443-3. Epub 2023 Sep 30. Br J Cancer. 2023. PMID: 37777577 Free PMC article.
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database.
Pommier P, Xie W, Ravi P, Carrie C, Dignam JJ, Feng F, Sargos P, Sommer SG, Spratt DE, Tombal B, Van Poppel H, Sweeney C. Pommier P, et al. Among authors: sweeney c. Radiother Oncol. 2024 Dec;201:110532. doi: 10.1016/j.radonc.2024.110532. Epub 2024 Sep 13. Radiother Oncol. 2024. PMID: 39278317 Free article.
Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma.
Fankhauser CD, Jandari A, Collette L, Tandstad T, Jiang DM, De Giorgi U, Sweeney C, Terbuch A, Chovanec M, Huddart R, Bokemeyer C, Beyer J, Gillessen S. Fankhauser CD, et al. Among authors: sweeney c. Eur Urol Open Sci. 2023 Sep 9;56:25-28. doi: 10.1016/j.euros.2023.08.008. eCollection 2023 Oct. Eur Urol Open Sci. 2023. PMID: 37711670 Free PMC article.
Top advances of the year: Genitourinary cancer.
Jackson-Spence F, Young M, Sweeney C, Powles T. Jackson-Spence F, et al. Among authors: sweeney c. Cancer. 2023 Sep 1;129(17):2603-2609. doi: 10.1002/cncr.34907. Epub 2023 Jun 28. Cancer. 2023. PMID: 37378532 Free article.
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT. Sutera P, et al. Among authors: sweeney c. Eur Urol Oncol. 2024 Apr;7(2):241-247. doi: 10.1016/j.euo.2023.07.014. Epub 2023 Aug 8. Eur Urol Oncol. 2024. PMID: 37558543 Free article.
1,180 results